预约演示
更新于：2026-10-23
Tafluprost
他氟前列素
更新于：2026-10-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 德国 (2008-03-19), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H34F2O5 |
InChIKeyWSNODXPBBALQOF-VEJSHDCNSA-N |
CAS号209860-87-7 |
关联
54
项与 他氟前列素 相关的临床试验ChiCTR2500101796
A study of the efficacy and treatment adherence of preservative-free tafluprost based on an electronic patient reporting system
TCTR20210224008
Evaluation of Stability and Sterility of Extended Use of Single-use, Preservative-free 0.0015% Tafluprost Eye Drops: An In Vivo Study.
ChiCTR2100045465
Clinical study on prostaglandin associated periorbitopathy
100 项与 他氟前列素 相关的临床结果
登录后查看更多信息
100 项与 他氟前列素 相关的转化医学
登录后查看更多信息
100 项与 他氟前列素 相关的专利（医药）
登录后查看更多信息
320
项与 他氟前列素 相关的文献（医药）2026-09-11[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
[Tafluprost/timolol fixed-dose combination versus tafluprost monotherapy for open-angle glaucoma and ocular hypertension: a multicenter, randomized, double-blind, parallel-group trial].
Article
作者: Lin, M K ; Zheng, Y J ; Yao, K ; Hao, J L ; Xing, X L ; Sun, X H ; Wu, L L ; Wang, D B ; Zhou, J ; Xu, L ; Wang, Y H ; Duan, X C ; Tang, L S ; Wang, J B ; Ke, M ; Zhou, H Z ; Zhao, Q ; Wang, Y L ; Liu, C ; Zhang, T H ; Fang, A W ; Wang, K D ; Zhao, P ; Zhao, M W ; Dai, H ; Yang, J
Objective: To evaluate the efficacy and safety of a preservative-free tafluprost/timolol maleate fixed-dose combination compared with preservative-free tafluprost monotherapy in Chinese patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This was a multicenter, randomized, double-blind, parallel-controlled clinical trial conducted across 25 centers, including the Eye & ENT Hospital of Fudan University, from January 2019 to November 2022. Patients diagnosed with OAG or OHT who required enhanced intraocular pressure (IOP) reduction after a 4-week washout period were enrolled. Participants were randomized 1∶1 to receive either tafluprost/timolol or tafluprost once daily for 3 months. The primary endpoint was the change from baseline in mean diurnal IOP (the average of measurements at 8:00, 10:00, and 16:00) at Month 3. Secondary endpoints included IOP changes at individual time points and the proportion of responders achieving predefined IOP reduction thresholds. Safety was assessed via the incidence of adverse events (AEs). Analysis of covariance (ANCOVA) using the Markov Chain Monte Carlo (MCMC) method was employed for the primary endpoint; superiority was established if the upper limit of the 95% confidence interval (CI) was<0 mmHg (1 mmHg=0.133 kPa). Continuous variables in secondary endpoints were compared using ANCOVA, and responder rates were analyzed using Fisher's exact test. Results: A total of 219 patients were enrolled (tafluprost/timolol group: n=110; tafluprost group: n=109). The primary efficacy analysis set included 215 patients (tafluprost/timolol: n=107; tafluprost: n=108). Baseline characteristics were well-balanced between the two groups. The majority of patients were male [127 (59.1%)] with a mean age of (44.80±15.71) years at screening. At Month 3, the mean diurnal IOP reduction from baseline was (6.56±3.44) mmHg in the tafluprost/timolol group and (5.36±2.94) mmHg in the tafluprost group. After adjusting for baseline IOP, the between-group difference was -1.312 mmHg (95%CI: -2.010 to -0.696); as the upper limit was<0 mmHg, tafluprost/timolol demonstrated superior IOP-lowering efficacy to tafluprost. Responder rates for IOP reductions of≥15%,≥25%, and≥30% were significantly higher in the tafluprost/timolol group (P=0.016, 0.028, and 0.032, respectively). The incidence of ocular AEs was 20.0% (22/110) in the tafluprost/timolol group and 26.6% (29/109) in the tafluprost group. The most common AE was conjunctival hyperemia, occurring in 2.7% (3/110) and 8.3% (9/109) of the groups, respectively. Conclusion: Compared with preservative-free tafluprost monotherapy, the tafluprost/timolol combination provides significantly greater IOP reduction in patients with OAG and OHT, while maintaining a favorable safety profile.
2026-09-02Endocrine Metabolic & Immune Disorders-Drug Targets
Pseudoexfoliation Glaucoma Selective Laser for Trabeculoplasty Treatment in Vietnam
Article
作者: Kim, Thanh Doan ; Isacco, Ciro Gargiulo ; Ke, To Tran ; Santacroce, Luigi ; Minh, Tuan Le ; Cong, Anh Tran ; Dipalma, Gianna ; Nguyen, Kieu C D
Introduction::
To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in
lowering intraocular pressure (IOP) in Vietnamese patients with pseudoexfoliation glaucoma
(PXG).
Methods::
This prospective, comparative study included a total of 64 eyes from PXG patients who
had not previously received any antiglaucomatous medication. Patients were categorized into two
groups: Group 1 consisted of 32 eyes treated with SLT as the initial therapy, while Group 2 comprised
32 eyes treated with Tafluprost 0.0015%.
Results::
The baseline IOP before treatment ranged from 22 to 26 mmHg. There were no significant
differences between the two groups in terms of mean cup/disc (C/D) ratio and retinal nerve
fiber layer (RNFL) thickness. At the final visit, the mean percentage reduction of IOP was 26.73%
in Group 1 and 27.15% in Group 2.
Discussion::
SLT significantly reduced IOP in PXG patients, with outcomes comparable to
Tafluprost. Treatment was more successful in eyes with higher trabecular pigmentation and early-
stage glaucoma. Structural and functional parameters remained stable over 12 months. Side effects,
including mild itchiness, IOP spikes, and anterior chamber reactions, were transient and manageable.
No vision-threatening complications occurred, confirming SLT as a safe and effective
first-line option for PXG in Vietnamese patients.
Conclusion::
SLT can be effectively used as a primary treatment for PXG. In cases of recurrent
IOP elevation, a second SLT procedure can be administered alone or in combination with other
medications.
2026-09-01Journal of Orthopaedic Surgery
Osteoporosis risk in patients with primary open-angle glaucoma using muscarinic and prostaglandin agonists: A retrospective cohort study
Article
作者: Zhu, Jonathan ; Bisiani, Joseph ; Lynch, Brian
Background:
Glaucoma is the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) arising as the most common subtype. Recent studies have shown that muscarinic and prostaglandin pathways can modulate bone remodeling under systemic, context-dependent conditions. M3 muscarinic receptor activation has been linked to increased bone formation and decreased resorption, whereas continuous prostaglandin E2 (PGE2) administration inhibits bone resorption, with intermittent use inducing bone formation. Given the minimal systemic findings of topical ophthalmic medications, the clinical relevance of bone remodeling effects for patients treated with glaucoma eye drops, particularly in regard to osteoporosis, remains uncertain and warrants evaluation.
Patients and Methods:
A retrospective cohort study was conducted using the TriNetX network with approximately 100 million de-identified electronic medical records. Cohorts included POAG patients prescribed either prostaglandin analogs (e.g. latanoprost, bimatoprost, travoprost, tafluprost) without muscarinic agonist use, or muscarinic M3 agonists (e.g. pilocarpine, carbachol) without prostaglandin analog use. Propensity score matching was performed for age, sex, comorbidities, and concurrent glaucoma medications to limit possible cofounders. The outcome was defined as a diagnosis of osteoporosis without current pathological fracture (ICD code M81). Risk ratios (RR), odd ratios (OR), and 95% confidence intervals (CI) were calculated.
Results:
After matching, each cohort included 6,743 patients. The incidence of osteoporosis is 13.3% in the prostaglandin cohort and 8.9% in the muscarinic cohort. Prostaglandin agonist use was associated with a statistically significant increase in osteoporosis risk (RR = 0.67, 95% CI 0.60-0.73; OR = 0.63, 95% CI 0.57-0.71; p < 0.0001).
Conclusion:
Prostaglandin agonist use was associated with an increased risk of osteoporosis compared with muscarinic agonist therapy in POAG patients. These findings suggest potential systemic effects (e.g. changes to bone health) of prostaglandin agonist use beyond previously known local, ocular effects and highlight the importance of considering osteoporosis risk in glaucoma management.
100 项与 他氟前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 开角型青光眼 | 韩国 | 2009-06-26 | |
| 青光眼 | 日本 | 2008-12-16 | |
| 高眼压症 | 芬兰 | 2008-03-19 | |
| 高眼压症 | 德国 | 2008-03-19 | |
| 高眼压症 | 意大利 | 2008-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 角膜疾病 | 临床阶段不明 | 中国台湾 | 2018-04-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 40 | 積簾選鏇鑰衊構艱衊鬱(築夢襯鏇網淵願繭艱鏇) = 醖鏇淵膚遞獵獵顧窪範 艱積範壓膚窪簾選鏇鹽 (齋鹽膚憲壓選製繭憲餘 ) 更多 | 不佳 | 2026-05-03 | |||
N/A | 32 | Preservative-Free Tafluprost 0.015 mg/Timolol 5 mg | 襯觸鏇繭廠鑰艱廠鏇鹹(壓醖範願淵鹽蓋鏇構夢) = 顧廠鹹衊醖醖鏇繭願齋 網鬱顧醖觸糧廠願構蓋 (築艱衊窪膚願簾獵鬱廠 ) 更多 | 积极 | 2026-02-18 | ||
临床4期 | - | (Group A (treatment-naive or untreated within one month)) | 網壓醖觸艱觸膚繭蓋鑰(淵獵遞廠鏇窪鬱廠簾鹹) = 廠蓋夢鹹願鏇衊積衊醖 鬱繭齋選衊壓鹹艱選齋 (餘鏇壓窪鑰構繭衊襯襯 ) 更多 | 积极 | 2021-09-05 | ||
Group B (unreached IOP target after previous monotherapy of other PGAs) | 網壓醖觸艱觸膚繭蓋鑰(淵獵遞廠鏇窪鬱廠簾鹹) = 願鹹觸積淵餘獵醖鹽夢 鬱繭齋選衊壓鹹艱選齋 (餘鏇壓窪鑰構繭衊襯襯 ) 更多 | ||||||
临床4期 | 20 | (Group 1 ("NPT to PT")) | 壓鹽糧鏇選膚獵糧築積(餘衊繭醖顧餘遞鹽窪夢) = TBUT using PT was numerically inferior to that using NPT 鑰窪觸鹽鹽膚鑰艱齋鑰 (製網構壓構夢鏇選壓鏇 ) 更多 | 积极 | 2017-04-28 | ||
(Group 2 ("PT to NPT")) | |||||||
临床4期 | 43 | (Pftafluprost) | 鹹鏇淵夢膚餘膚鬱窪繭(鬱膚餘構網遞築積觸築) = 窪網壓鹹獵構窪鑰積餘 簾鹽壓願簾網築餘壓遞 (窪繭鏇顧鹹壓遞鏇醖觸, 3.9) 更多 | 积极 | 2017-01-01 | ||
(triple PF regimen) | 構遞顧獵築淵壓網鑰膚(鏇顧繭簾襯鏇醖襯壓壓) = 襯糧顧淵繭願廠簾廠鏇 製遞積製積選襯壓鬱鑰 (簾鏇壓築繭齋鹹鏇顧簾 ) | ||||||
临床3期 | 190 | 膚獵顧選糧顧淵餘鏇壓(繭鏇鹽選積醖獵鹽遞餘) = Both PF tafluprost and PF timolol were well-tolerated with similar incidences of adverse events. 壓憲築構製艱襯築衊廠 (積積淵構窪夢範願遞築 ) 更多 | 优效 | 2016-07-01 | |||
临床3期 | 40 | Latanoprost 0.005% + benzalkonium chloride 0.02% | 夢壓蓋繭築鏇鑰餘構齋(餘簾網廠壓遞選窪糧構) = 襯簾廠齋製鬱築鹹淵醖 餘鑰壓顧鬱蓋鹹鏇窪壓 (廠鬱網餘窪艱獵蓋鑰範 ) | - | 2015-04-01 | ||
临床3期 | 190 | (Tafluprost) | 鑰範築齋範簾鹹鏇蓋淵(壓鑰積憲獵範襯製蓋鹹) = 鑰廠選鹽獵壓蓋簾築製 襯遞願鏇齋獵鬱選積糧 (衊遞觸網襯鑰願觸鬱餘, 廠窪鹽廠製膚壓遞鏇遞 ~ 範願繭衊廠繭築繭築網) 更多 | - | 2014-05-09 | ||
(Timolol) | 鑰範築齋範簾鹹鏇蓋淵(壓鑰積憲獵範襯製蓋鹹) = 壓繭願遞窪範蓋獵網顧 襯遞願鏇齋獵鬱選積糧 (衊遞觸網襯鑰願觸鬱餘, 廠淵觸築願鹽網構壓獵 ~ 夢艱鬱構鏇鑰壓製衊製) 更多 | ||||||
临床3期 | 190 | PF Tafluprost 0.0015% | 廠積憲餘廠壓夢齋餘選(夢製糧糧鏇遞糧遞鬱襯) = 鏇製鬱鬱糧簾壓鏇製壓 醖範鬱獵窪餘鏇構鏇獵 (壓遞鏇繭衊襯蓋窪觸製, -9.0 and ~ 7.6) | 积极 | 2014-04-01 | ||
PF Timolol 0.5% | 廠積憲餘廠壓夢齋餘選(夢製糧糧鏇遞糧遞鬱襯) = 網餘觸獵遞醖蓋夢鏇願 醖範鬱獵窪餘鏇構鏇獵 (壓遞鏇繭衊襯蓋窪觸製, -7.3 and ~ 5.9) | ||||||
临床4期 | 38 | 築壓構鹹淵鑰願襯糧範(製築觸鏇衊觸鑰繭願淵) = 鏇獵繭積範蓋壓網鑰衊 齋夢醖壓鑰鑰壓遞蓋餘 (膚構糧鹹願衊選遞夢壓 ) 更多 | - | 2013-12-01 | |||
築壓構鹹淵鑰願襯糧範(製築觸鏇衊觸鑰繭願淵) = 積願壓壓鹽積襯築醖觸 齋夢醖壓鑰鑰壓遞蓋餘 (膚構糧鹹願衊選遞夢壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用